| Literature DB >> 35706042 |
Michele Costanzo1,2, Marianna Caterino3,4, Giovanni Sotgiu5, Margherita Ruoppolo3,4, Flavia Franconi6, Ilaria Campesi6,7.
Abstract
BACKGROUND: The sexual dimorphism represents one of the triggers of the metabolic disparities between the organisms, advising about wild implications in research or diagnostics contexts. Despite the mounting recognition of the importance of sex consideration in the biomedical fields, the identification of male- and female-specific metabolic signatures has not been achieved. MAIN BODY: This review pointed the focus on the metabolic differences related to the sex, evidenced by metabolomics studies performed on healthy populations, with the leading aim of understanding how the sex influences the baseline metabolome. The main shared signatures and the apparent dissimilarities between males and females were extracted and highlighted from the metabolome of the most commonly analyzed biological fluids, such as serum, plasma, and urine. Furthermore, the influence of age and the significant interactions between sex and age have been taken into account.Entities:
Keywords: Age; Biomarkers; Liquid biopsy; Metabolic signature; Metabolomics; Sex differences
Mesh:
Year: 2022 PMID: 35706042 PMCID: PMC9199320 DOI: 10.1186/s13293-022-00440-4
Source DB: PubMed Journal: Biol Sex Differ ISSN: 2042-6410 Impact factor: 8.811
Classification of the 32 eligible studies selected for the review according to the score system
| First author and year | Experimental design | Methodology | Novelty | Final score | Classification | |||
|---|---|---|---|---|---|---|---|---|
| N of subjects (per sex) | Age stratification | Analytical platform | Statistical support | Validation | ||||
| Chekmeneva E. 2018 [ | 2 | 1 | 3 | 2 | 1 | 1 | 10 | Excellent |
| Dunn W. B. 2014 [ | 2 | 2 | 3 | 2 | 0 | 1 | 10 | Excellent |
| Lawton K. A. 2008 [ | 2 | 2 | 3 | 1 | 0 | 1 | 9 | Excellent |
| Saito K. 2016 [ | 1 | 2 | 3 | 2 | 0 | 1 | 9 | Excellent |
| Andraos S. 2021 [ | 2 | 2 | 2 | 1 | 0 | 1 | 8 | Good |
| Caterino M. 2021 [ | 2 | 1 | 2 | 2 | 0 | 1 | 8 | Good |
| Lau C.-H. E. 2018 [ | 2 | 1 | 3 | 2 | 0 | 0 | 8 | Good |
| Rist M. J. 2017 [ | 2 | 0 | 3 | 2 | 0 | 1 | 8 | Good |
| Ruoppolo M. 2015 [ | 2 | 1 | 2 | 2 | 0 | 1 | 8 | Good |
| Trabado S. 2017 [ | 2 | 1 | 2 | 2 | 0 | 1 | 8 | Good |
| Zaura E. 2017 [ | 2 | 1 | 2 | 2 | 0 | 1 | 8 | Good |
| Bell J. A. 2021 [ | 2 | 2 | 1 | 1 | 0 | 1 | 7 | Good |
| Caterino M. 2020 [ | 2 | 2 | 1 | 1 | 0 | 1 | 7 | Good |
| De Paepe E. 2018 [ | 0 | 1 | 2 | 2 | 1 | 1 | 7 | Good |
| Jovè M. 2016 [ | 2 | 0 | 2 | 2 | 0 | 1 | 7 | Good |
| Liang Q. 2015 [ | 0 | 1 | 2 | 2 | 1 | 1 | 7 | Good |
| Mittelstrass K. 2011 [ | 2 | 0 | 2 | 2 | 0 | 1 | 7 | Good |
| Scalabre A. 2017 [ | 2 | 2 | 1 | 2 | 0 | 0 | 7 | Good |
| Thévenot E. A. 2015 [ | 2 | 1 | 2 | 2 | 0 | 0 | 7 | Good |
| Yu Z. 2012 [ | 2 | 0 | 2 | 2 | 0 | 1 | 7 | Good |
| Fan S. 2018 [ | 2 | 0 | 1 | 2 | 0 | 1 | 6 | Good |
| Gallart-Ayala H. 2018 [ | 0 | 1 | 2 | 1 | 1 | 1 | 6 | Good |
| Li Z. 2018 [ | 2 | 1 | 2 | 1 | 0 | 0 | 6 | Good |
| Ruoppolo M. 2014 [ | 2 | 1 | 2 | 1 | 0 | 0 | 6 | Good |
| Slupsky C. M. 2007 [ | 2 | 0 | 1 | 2 | 0 | 1 | 6 | Good |
| Tsoukalas D. 2019 [ | 2 | 2 | 1 | 1 | 0 | 0 | 6 | Good |
| Vignoli A. 2018 [ | 2 | 1 | 1 | 2 | 0 | 0 | 6 | Good |
| Das M. K. 2014 [ | 0 | 1 | 1 | 2 | 0 | 1 | 5 | Fair |
| Hirschel J. 2020 [ | 2 | 0 | 2 | 1 | 0 | 0 | 5 | Fair |
| Jarrell Z. R. 2020 [ | 2 | 0 | 2 | 1 | 0 | 0 | 5 | Fair |
| Reavis Z. W. 2021 [ | 2 | 1 | 0 | 2 | 0 | 0 | 5 | Fair |
| Takeda I. 2009 [ | 1 | 0 | 1 | 2 | 0 | 1 | 5 | Fair |
Fig. 1Schematic flow diagram of the entire review process
Summary of the characteristics of the 20 studies included in the review
| First author and year | Country/ethnicity | Subjects (total n) | Sex (total n) | Age/age groups | Biologic matrix | Analytical platform | Statistics | Quality score |
|---|---|---|---|---|---|---|---|---|
| Andraos S. 2021 [ | Australia | 1166 1324 | 565 M 601 F 174 M 1150 F | 11.4 ± 0.5 11.5 ± 0.5 46.2 ± 6.4 43.6 ± 4.8 years (mean ± SD) | Plasma | UHPLC–MS/MS | Linear mixed-effects models Pearson’s correlation | 8 |
| Caterino M. 2020 [ | Italy | 291 | 152 M 139 F | (1–36 months) 1–6 months 7–12 months 13–24 months 25–36 months | Urine | GC–MS | Dunn’s test Kruskal–Wallis test Mann–Whitney U test | 7 |
| Caterino M. 2021 [ | Italy | 311 | 174 M 137 F | 48–72 h | DBS | LC–MS/MS | Spearman’s correlation PLS-DA VIP | 8 |
| Chekmeneva E. 2018 [ | USA | 132 | N. F. | 40–59 years | Urine | 1H NMR DI-nESI-HRMS UPLC–HRMS | PCA OPLS-DA | 10 |
| De Paepe E. 2018 [ | Belgium | 10 | 5 M 5 F | 25–41 years | Plasma Urine | UHPLC–MS/MS | CV-ANOVA PCA OPLS-DA | 7 |
| Dunn W. B. 2014 [ | UK | 1200 | N. F. | (19–81 years) < 40 years 40–49 years 50–64 years > 64 years | Serum | UPLC–MS (+) UPLC–MS (−) GC–MS | ANOVA Kruskal–Wallis test Mann–Whitney U test PLS-DA Random Forests | 10 |
| Fan S. 2018 [ | USA | 120 | 60 M 60 F | N. F. | Urine | GC–MS | Mann–Whitney U test PLS-DA PCA | 6 |
| Jovè M. 2016 [ | Spain | 146 | 68 M 78 F | 30–100 years | Plasma | LC–MS/MS (+) LC–MS/MS (−) | ANOVA PCA Student’s | 7 |
| Lau C.-H. E. 2018 [ | UK France Spain Lithuania Norway Greece | (1192) 199 157 207 201 229 199 | (54.6% M 45.4% F) | 6–11 years | Serum Urine | 1H NMR FIA-MS/MS LC–MS/MS | MWAS with multiple linear regression PCA Pearson’s correlation | 8 |
| Lawton K. A. 2008 [ | Caucasian African-American Hispanic | (269) 61 135 73 | (131 M, 138 F) 20M, 41 F 69 M, 66 F 42 M, 31 F | (20–65 years) 20–35 years 36–50 years 51–65 years | Plasma | LC–MS (+) LC–MS (−) GC–MS | ANCOVA ANOVA | 9 |
| Mittelstrass K. 2011 [ | Germany | 3080 377 | 1452 M, 1552 F 197 M, 180 F | 32–81 years 55–79 years | Serum | LC–MS/MS | PLS Linear regression Partial correlation analysis | 7 |
| Rist M. J. 2017 [ | Germany | 200 | 99 M 101 F | 36–80 years | Plasma Urine | 1H NMR FIA-MS/MS GC(xGC)-MS HILIC-MS/MS UHPLC–MS/MS | Glmnet PLS SVM | 8 |
| Ruoppolo M. 2014 [ | Italy | 76 | 35 M 41 F | 20–45 years | Serum | HPLC LC–MS/MS | SAM Pearson’s correlation Spearman’s correlation | 6 |
| Ruoppolo M. 2015 [ | Italy | 3680 | 1856 M 1824 F | 48–72 h | DBS | LC–MS/MS | Mann–Whitney U test Linear regression PCA | 8 |
| Saito K. 2016 [ | Japan | 60 | 15 M 15 F 15 M 15 F | 25–35 years 25–35 years 55–64 years 55–65 years | Serum | GC–MS HILIC–MS (−) UHPLC–MS (+) UHPLC–MS (−) | Welch’s two-factor PCA | 9 |
| Scalabre A. 2017 [ | France | 90 | 66 M 24 F | (< 4 mo) < 1 mo 1 months 2 months 3 months | Urine | 1H NMR | PCA O-PLS CV-ANOVA SRV | 7 |
| Slupsky C. M. 2007 [ | Canada | 60 | 30 M 30 F | 16–69 years | Urine | 1H NMR | ANOVA Mann–Whitney U test PCA PLS-DA | 6 |
| Thévenot E. A. 2015 [ | France | 183 | 100 M 83 F | 40.9 ± 10.3 years (mean ± SD) | Urine | UHPLC–MS(/MS) | Mann–Whitney U test O-PLS Spearman’s correlation | 7 |
| Trabado S. 2017 [ | France | 800 | 417 M 383 F | 18–86 years 37.6 ± 17.2 (mean ± SD) | Plasma | FIA-MS/MS LC–MS/MS | CV-ANOVA OPLS-DA PCA | 8 |
| Vignoli A. 2018 [ | Italy | 844 | 661 M 183 F | 41.0 ± 12.0 years (median ± SD) | Plasma | 1H NMR | PLS-DA Wilcoxon rank-sum test | 6 |
Most of the categories/terms in the table were ordered alphabetically. Whereas not specified in the papers, the generic LC–MS/MS term was reported for targeted metabolomic analyses; ( +) and (-) refer to positive and negative ionization modes, respectively. Missing information are reported as N.F. (not found). mo = months, y = years, SD = standard deviation
Sex differences identified in the plasma metabolome for AA and AC
| First author and year | De Paepe E. 2018 [ | Jovè M. 2016 [ | Lawton K. A. 2008 [ | Rist M. J. 2017 [ | Trabado S. 2017 [ | Vignoli A. 2018 [ | Andraos S. 2021 [ | ||
|---|---|---|---|---|---|---|---|---|---|
| Metabolite | Adults | Children | |||||||
| AA and analogues | Alanine | M | F | ||||||
| Arginine | M | ||||||||
| Asparagine | M | ||||||||
| Aspartate | M | ||||||||
| BCAA | M | M | M | M | M | M | |||
| Citrulline | M | M | |||||||
| Creatine | M | F | F | F | |||||
| Creatinine | M | M | M | M | |||||
| Cysteine | M | M | |||||||
| Glutamate | M | M | M | ||||||
| Glutamine | M | M | M | F | |||||
| Glycine | F | F | F | F | |||||
| Histidine | M | ||||||||
| Homocysteine | M | ||||||||
| Kynurenine | M | M | |||||||
| Lysine | F | ||||||||
| Methionine | M | M | |||||||
| M | |||||||||
| Phenylalanine | M | M | M | M | |||||
| OH-proline | M | M | F | ||||||
| Oxoproline | M | ||||||||
| Proline | M | M | |||||||
| Sarcosine | F | ||||||||
| Serine | F | F | |||||||
| Threonine | F | ||||||||
| Tyrosine | M | M | M | ||||||
| Tryptophan | F | M | M | M | |||||
| AC | C0 | M | M | ||||||
| C3 | M | ||||||||
| C5 | M | ||||||||
M, higher levels of the metabolite identified in male individuals; F, higher levels of the metabolite identified in female individuals. Hereon, whereas not specified, the age of the individuals treated in the papers is referred to adults
Sex differences identified in the serum metabolome for AA
| Adults | Children | Infants | ||||||
|---|---|---|---|---|---|---|---|---|
| First author and year | Dunn W. B. 2014 [ | Mittelstrass K. 2011 [ | Ruoppolo M. 2014 [ | Saito K. 2016 [ | Lau C.-H. E. 2018 [ | Caterino M. 2021 [ | Ruoppolo M. 2015 [ | |
| Metabolite | ||||||||
| AA and analogues | Alanine | F | F | |||||
| Arginine | M | |||||||
| Asparagine | M | M | ||||||
| Aspartate | F | F | ||||||
| BCAA | M | M | F | |||||
| Citrulline | M | M | F | F | ||||
| Creatine | F | |||||||
| Creatinine | F | M | ||||||
| Cysteine | M | |||||||
| Glutamine | M | M | F | |||||
| Glutamate | M | M | F | |||||
| Glycine | F | F | F | |||||
| Histidine | M | |||||||
| Lysine | M | F | ||||||
| Methionine | M | M | F | |||||
| Methionine sulfoxide | F | |||||||
| Ornithine | M | M | F | F | ||||
| Phenylalanine | M | F | ||||||
| Proline | M | M | ||||||
| Serine | F | F | ||||||
| Threonine | M | |||||||
| Tryptophan | F | M | ||||||
| Tyrosine | F | M | M | F | F | |||
| Putrescine | F | |||||||
| M | ||||||||
| Serotonin | M | M | ||||||
| Caffeine | F | |||||||
M, higher levels of the identified metabolite in male individuals; F, higher levels of the identified metabolite in female individuals
Sex differences identified in the serum metabolome for AC
| Adults | Children | Infants | ||||||
|---|---|---|---|---|---|---|---|---|
| First author and year | Dunn W. B. 2014 [ | Mittelstrass K. 2011 [ | Ruoppolo M. 2014 [ | Saito K. 2016 [ | Lau C.-H. E. 2018 [ | Caterino M. 2021 [ | Ruoppolo M. 2015 [ | |
| Metabolite | ||||||||
| AC | C0 | M | M | |||||
| C2 | M | |||||||
| C3 | M | |||||||
| C4 | F | |||||||
| C5 | M | F | ||||||
| C6 | M | |||||||
| C8 | M | |||||||
| C10 | M | M | F | M | ||||
| C12 | M | F | M | |||||
| C14 | M | M | ||||||
| C16 | M | M | ||||||
| C18 | M | |||||||
| C5:1 | M | F | ||||||
| C6:1 | F | |||||||
| C8:1 | F | |||||||
| C10:1 | M | M | ||||||
| C10:2 | F | |||||||
| C14:1 | F | M | ||||||
| C14:2 | F | |||||||
| C16:1 | F | M | ||||||
| C18:1 | M | M | M | |||||
| C18:2 | M | M | M | |||||
| C4OH | M | |||||||
| C14OH | M | |||||||
| C16OH | M | |||||||
| C14:1OH | F | |||||||
| C18:1OH | M | |||||||
| C3DC | M | |||||||
| C4DC | M | |||||||
| C5DC | M | |||||||
| C8DC | M | |||||||
| C10DC | M | |||||||
M, higher levels of the metabolite identified in male individuals; F, higher levels of the metabolite identified in female individuals
Sex differences identified in the urine metabolome (part 1)
| Adults | Children | Infants | |||||||
|---|---|---|---|---|---|---|---|---|---|
| First author and year | Chekmeneva E. 2018 [ | De Paepe E. 2018 [ | Fan S. 2018 [ | Rist M. J. 2017 [ | Slupsky C. M. 2007 [ | Thévenot E. A. 2015 [ | Lau C.-H. E. 2018 [ | Scalabre A. 2017 [ | |
| Metabolite | |||||||||
| AA and analogues | 2-Aminoadipic acid | F | |||||||
| 2,6-Diaminopimelic acid | M | ||||||||
| 5-Oxoproline | M | ||||||||
| Acetyl phenylalanine | F | ||||||||
| Aminosalicyluric acid | F | ||||||||
| Creatine | F | F | F | ||||||
| Creatinine | M | M | M | ||||||
| M | |||||||||
| Glycine | F | ||||||||
| Isoleucine | F | ||||||||
| Leucine | M | ||||||||
| N-Acetylaspartic acid | F | ||||||||
| Nicotinuric acid | F | ||||||||
| Proline | M | ||||||||
| Tyrosine | M | ||||||||
| AC | C0 | M | |||||||
| C2 | M | ||||||||
| C3 | M | ||||||||
| C5 | M | ||||||||
| C6 | M | ||||||||
| C8 | M | ||||||||
| C9 | M | ||||||||
| C10 | M | M | |||||||
| C7:1 | M | ||||||||
| C8:1 | M | M | |||||||
| C9:1 | M | ||||||||
| C10:1 | M | M | |||||||
| C10:2 | M | ||||||||
| C10:3 | M | ||||||||
| C11:1 | M | ||||||||
| C8OH | M | ||||||||
| C6:1OH | M | ||||||||
| C10:2OH | M | ||||||||
| C5-M-DC | F | ||||||||
| C6DC | M | ||||||||
M, higher levels of the metabolite identified in male individuals; F, higher levels of the metabolite identified in female individuals
Sex differences identified in the urine metabolome (part 2)
| Adults | Children | Infants | |||||||
|---|---|---|---|---|---|---|---|---|---|
| First author and year | Chekmeneva E. 2018 [ | De Paepe E. 2018 [ | Fan S. 2018 [ | Rist M. J. 2017 [ | Slupsky C. M. 2007 [ | Thévenot E. A. 2015 [ | Lau C.-H. E. 2018 [ | Scalabre A. 2017 [ | |
| Metabolite | |||||||||
| OA | 2-Hydroxyglutaric acid | F | |||||||
| 2-Hydroxyphenyl acetic acid | M | ||||||||
| 3,4-Dihydroxy phenylacetic acid | M | ||||||||
| 4-Hydroxybutyric acid | M | ||||||||
| 4-Deoxythreonic acid | M | ||||||||
| α-Ketoglutaric acid | M | F | F | ||||||
| Capric acid | M | ||||||||
| Caprylic acid | M | ||||||||
| Citric acid | F | F | F | F | F | ||||
| Fumaric acid | F | F | F | ||||||
| Heptadecanoic acid | M | ||||||||
| Malic acid | F | F | |||||||
| Mevalonic acid | F | ||||||||
| Oxoglutaric acid | F | ||||||||
| Pantothenic acid | F | ||||||||
| Pelargonic acid | M | ||||||||
| Pyruvic acid | F | ||||||||
| Stearic acid | M | ||||||||
| Succinic acid | F | ||||||||
| carbohydrates | D-Fructose | F | F | ||||||
| Acetaminophen glucuronide | F | ||||||||
| Galactonic acid | F | ||||||||
| Gluconic acid | F | ||||||||
| Glucuronic acid | F | ||||||||
| Glyceric acid | F | ||||||||
| Lyxose | F | ||||||||
| Maltose | F | ||||||||
| Pentose | F | ||||||||
| Threonic acid | F | ||||||||
| UDP-glucuronic acid | M | ||||||||
| Xylose | F | ||||||||
| Acylglycines | 2-Methylhippuric acid | F | |||||||
| 3-Methylcrotonyl glycine | F | ||||||||
| Cinnamoylglycine | F | ||||||||
| Hippuric acid | F | ||||||||
| F | |||||||||
| Tiglylglycine | F | ||||||||
| Valerylglycine | F | ||||||||
| Xen | 1-Methylurate | M | |||||||
| 1-Methylxantine | M | ||||||||
| Caffeine | F | ||||||||
M, higher levels of the metabolite identified in male individuals; F, higher levels of the metabolite identified in female individuals. Xen, xenobiotics